343947-48-8

Usage

Uses

Used in Pharmaceutical Applications:
(3S)-3-(benzylamino)butan-2-ol is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activity and structural versatility. Its chiral nature allows for the development of enantiomer-specific drugs, which can have different effects in the body.
Used in Chemical Synthesis:
In the chemical industry, (3S)-3-(benzylamino)butan-2-ol is used as a building block for the creation of more complex organic molecules. Its unique structural features make it a valuable component in the synthesis of various compounds with specific applications.
Used in Research and Development:
(3S)-3-(benzylamino)butan-2-ol is utilized in research and development for studying the effects of chirality on biological activity and for developing new methods to produce enantiomerically pure compounds. This can lead to advancements in the fields of medicinal chemistry and drug discovery.
Used in Chiral Catalysts:
(3S)-3-(benzylamino)butan-2-ol may also find use in the development of chiral catalysts, which are essential in asymmetric synthesis to produce enantiomerically enriched products. These catalysts are crucial for creating pharmaceuticals and other chiral molecules with high selectivity and efficiency.

Upstream product

• 513-86-0 3-hydroxy-2-butanon 
• 100-46-9 benzylamine 
• 100-52-7 benzaldehyde 
• 226727-07-7 tert-butyl N-[(1S)-2-hydroxy-1-methylpropyl]carbamate 
• 925669-95-0 2,3-cis-epoxybutane 
• 40513-26-6 3-benzylamino-butan-2-one 
• 184047-86-7 Benzyl-[(S)-2-(tert-butyl-dimethyl-silanyloxy)-prop-(E)-ylidene]-amine 

Relevant academic research and scientific papers

6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

Chiral Titanium Coordination Assemblies: Robust Cooperative Self-Supported Catalysts for Asymmetric Ring Opening of meso-Epoxides with Aliphatic Amines

By utilizing the oxygen bridge in dimeric μ-oxo-titanium-salen complexes as an efficient cross-linkage, a series of robust chiral titanium coordination assemblies has been successfully fabricated with the ditopic bridging ligands derived from BINOL and salen derivatives via coordination polymerization, which are fully characterized by IR, elemental analysis, XRD and microscopic studies. Because of their insolubility in most organic solvents and water, these metal-organic assemblies can successfully function as robust self-supported chiral catalysts, allowing an asymmetric ring opening (ARO) of meso-epoxides with aliphatic amines. Remarkably, owing to the linkage effects and the cooperation of two kinds of chiral titanium moieties in the metal-organic assemblies, the self-supported chiral catalysts demonstrate extremely high stability. They not only show high tolerance towards various meso-epoxides and nucleophilic aliphatic amines, but also can be reused in more than 20 runs without obvious metal leaching and loss in yields and enantioselectivities. Furthermore, the self-supported catalyst accomplished a one-pot tandem olefin epoxidation and ARO of an epoxide sequence starting from the olefin, 30% hydrogen peroxide and benzylamine. In marked contrast, the reaction failed to work when using the two corresponding homogeneous catalysts under identical reaction conditions. Good yields and enantioselectivities were obtained by the robust self-supported catalyst, which clearly indicates the cooperative effects between two chiral moieties within the metal-organic assemblies. The two catalytic centers can perform their own duties without interference and this further supports our strategy for the self-supported catalyst design. (Figure presented.).

Structure-based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors

A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines. Use of PI3Kα mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chemistry designs. Detailed DMPK studies involving cyanide and GSH as trapping agents during microsomal incubations, in addition to deuterium-labeled compounds as mechanistic probes uncovered the molecular basis for the observed CYP3A4 TDI in the series. (Chemical Equation Presented).

NOVEL COMPOUNDS

Disclosed are N-{[(1R,4S,6R)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

Stereoselective synthesis of 1,2-amino alcohols by addition of organocuprate·BF3 complexes and organolithium reagents to an α-silyloxyaldimine derived from (S)-ethyl lactate

1,2-Amino alcohols were synthesized by addition of organocuprate·BF3 2 (R = n-Bu, n-octyl, Me, phenethyl, Ph), organocopper·BF3 3 (R = Me, n-Bu), and organolithiums (R = n-Bu, n-octyl, Me, phenethyl, Ph) to an α-silyloxyaldimine 1 derived from commercially available (S)-ethyl lactate. The reactions with organocuprate·BF3 2 and organocopper·BF3 3 led to the anti isomers almost exclusively (anti:syn = > 98: 2 for R = n-Bu, n-octyl, Me, phenethyl and anti:syn = 95:5 for R = Ph, 52-93% isolated yields) and the syn isomers could be obtained with high stereoselectivities by using organolithiums (anti:syn = 10:90-20:80, 41-71% isolated yields).